{
    "root": "87f00026-4a98-42c2-b241-8c1ec06a275a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": "Pirfenidone",
    "value": "20250501",
    "ingredients": [
        {
            "name": "PIRFENIDONE",
            "code": "D7NLD2JX7U"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI"
        },
        {
            "name": "POLYETHYLENE GLYCOL",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POLYVINYL ALCOHOL",
            "code": "532B59J990"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        }
    ],
    "indications": "pirfenidone indicated treatment idiopathic pulmonary fibrosis ( ipf ) .",
    "contraindications": "take food . recommended : 801 mg three times daily ( 2,403 mg/day ) . ( 2 ) upon initiation treatment , titrate full 2,403 mg/day 14-day period follows : treatment days days 1 7 267 mg three times daily ( 801 mg/day ) days 8 14 534 mg three times daily ( 1,602 mg/day ) days 15 onward 801 mg three times daily ( 2,403 mg/day ) consider temporary reduction , treatment interruption , discontinuation management . ( 2.3 , 5.1 , 5.2 , 5.3 , 5.4 ) prior treatment , conduct liver function tests . ( 2.1 )",
    "warningsAndPrecautions": "pirfenidone film-coated tablets available 267 mg 801 mg strengths supplied follows : 267 mg - yellow colored , oval shaped , biconvex film-coated tablets debossed “ n869 ” one side plain side . ndc 70954-869-10 , carton containing 3 bottles , containing ninety 267 mg tablets ( 270 tablets total ) child-resistant closure ndc 70954-869-30 , bottle containing two hundred seventy 267 mg tablets , child-resistant closure 801 mg - brown colored , oval shaped , biconvex film-coated tablets debossed “ n870 ” one side plain side . ndc 70954-870-10 , bottle containing ninety 801 mg tablets , child-resistant closure store 20° 25°c ( 68° 77°f ) , excursions permitted 15° 30°c ( 59° 86°f ) . [ usp controlled room temperature . ] keep bottle tightly closed . seal bottle opening broken missing . safely throw away pirfenidone tablets date longer needed .",
    "adverseReactions": "none .",
    "indications_original": "Pirfenidone is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).",
    "contraindications_original": "Take with food. Recommended dosage: 801 mg three times daily (2,403 mg/day). ( 2 ) Upon initiation of treatment, titrate to the full dosage of 2,403 mg/day over a 14-day period as follows: Treatment days Dosage Days 1 through 7 267 mg three times daily (801 mg/day) Days 8 through 14 534 mg three times daily (1,602 mg/day) Days 15 onward 801 mg three times daily (2,403 mg/day) Consider temporary dosage reduction, treatment interruption, or discontinuation for management of adverse reactions. ( 2.3 , 5.1 , 5.2 , 5.3 , 5.4 ) Prior to treatment, conduct liver function tests. ( 2.1 )",
    "warningsAndPrecautions_original": "Pirfenidone film-coated tablets are available in 267 mg and 801 mg strengths and supplied as follows: \n                  \n                  267 mg - Yellow colored, oval shaped, biconvex film-coated tablets debossed with “N869” on one side and plain on other side.\n                  \n                  \n                     NDC 70954-869-10, carton containing 3 bottles, each containing ninety 267 mg tablets (270 tablets total) with a child-resistant closure\n                     NDC 70954-869-30, bottle containing two hundred and seventy 267 mg tablets, with a child-resistant closure\n                  \n                  \n                  \n                     801 mg - Brown colored, oval shaped, biconvex film-coated tablets debossed with “N870” on one side and plain on other side.\n                  \n                  \n                  \n                     NDC 70954-870-10, bottle containing ninety 801 mg tablets, with a child-resistant closure\n                  \n                  \n                  Store at 20° to 25°C (68° to 77°F), excursions permitted between 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature.]\n                  \n                  Keep the bottle tightly closed. Do not use if the seal over the bottle opening is broken or missing. Safely throw away any pirfenidone tablets that are out of date or no longer needed.",
    "adverseReactions_original": "None."
}